This feature highlights changes in clinical trial organizations’ personnel.

Albumedix

Gregor Kawaletz was named chief commercial officer of Albumedix. Previously, Kawaletz was chief commercial officer at IDT Biologika.

Aruvant Sciences

V. “Palani” Palaniappan has been appointed to the role of chief technology officer at Aruvant Sciences. Prior to Aruvant, Palaniappan was senior vice president and head of global technical operations at Sarepta.

Confo Therapeutics

Confo Therapeutics has named Paolo Vicini the company’s chief development officer. Prior to this role, Vicini was vice president of development sciences at Kymab.

Cytovia Therapeutics

Wei Li has been appointed chief scientific officer at Cytovia Therapeutics. Li was most recently chief development officer at OliX Pharmaceuticals.

EpicentRx

EpicentRx has named Tony Reid to lead the company as its CEO. Reid is a co-founder of EpicentRx and formerly served as the company’s chief scientific officer.

Ferring Pharmaceuticals

Brent Ragans will now serve as the president of Ferring Pharmaceuticals, a role that will oversee the company’s commercial, manufacturing and development operations. Ragans served as chief commercial officer for Ferring prior to this new position.

Flagship Pioneering

Fabrice Chouraqui, former president of Novartis Pharmaceuticals, was appointed by Flagship Pioneering to the newly created dual role of Flagship CEO-partner and CEO of Cellarity.

Gilead Sciences

Mark Genovese was appointed senior vice president of Gilead’s inflammation division. Genovese was recently the James W. Raitt professor of medicine and clinical chief of the division of immunology and rheumatology at Stanford University.

ImmunoGen

ImmunoGen has hired Stacy Coen to the role of senior vice president and chief business officer. Coen served as vice president of business development at Editas Medicine prior to joining ImmunoGen.

Ipsen

David Loew, tapped from his CEO position at Sanofi, has been appointed CEO of Ipsen.

Nimbus Therapeutics

Alan Collis has been promoted from the role of vice president to senior vice president of preclinical development at Nimbus Therapeutics. Before joining Nimbus in 2019, Collis was executive director of drug metabolism and pharmacokinetics at Forma Therapeutics.

Roche

Roche has named V. Simpson Emmanuel general manager of Roche Products (India). Emmanuel most recently held the position of access innovation leader at Roche Pharma international.

Samumed

Michael White has been named chief scientific officer of Samumed, joining the company from his most recent position as vice president and chief scientific officer at Pfizer.

Sanifit

Sanifit has named Hans Christian Keller the company’s vice president of business development. Most recently, Keller was senior director of global business development at Lundbeck. Sanifit has also hired Laura Williams to the role of senior vice president of clinical development. Williams recently served as senior vice president and head of clinical development and biostatistics at AMAG Pharma.

Sanofi

Sanofi has appointed Thomas Triomphe to head Sanofi Pasteur; Julie Van Ongevalle to head of consumer healthcare; Arnaud Robert to chief digital officer, and Natalie Bickford to chief people officer. In their previous roles, Triomphe served as head of franchises and product strategy at Sanofi Pasteur; Ongevalle served as global brand president of Origins; Robert was chief digital officer at Viking Cruises, and Bickford was the group human resources director at Merlin Entertainments.

Spectrum Pharmaceuticals

Lyndah Dreiling has been named senior vice president of clinical development at Spectrum Pharmaceuticals. Dreiling was most recently the vice president and head of clinical development at Five Prime Therapeutics.

SwanBio Therapeutics

SwanBio Therapeutics has appointed Steven Zelenkofske to the role of chief medical officer. Zelenkofske joins SwanBio from Achillion Pharmaceuticals, where he served as executive vice president and chief medical officer.

Wave Life Sciences

Kenneth Rhodes, co-founder and former chief scientific officer of Yumanity Therapeutics, has been named senior vice president of therapeutics discovery at Wave Life Sciences.

WuXi AppTec

David Chang has been tapped to lead the WuXi AppTec advanced therapies business unit as its newest CEO. Previously, Chang was corporate vice president and head of cell therapy global manufacturing at Celgene.